InvestorsHub Logo
Followers 140
Posts 11663
Boards Moderated 0
Alias Born 03/15/2011

Re: jimsgtx post# 314728

Friday, 10/20/2017 8:23:35 AM

Friday, October 20, 2017 8:23:35 AM

Post# of 346653
jim, yes. But my fear is that it is going in hands were you CANNOT FOLLOW it or where you cannot substantially follow it for the price they sell it.

Examples:
A) It goes to a NON LISTED party.

B) It goes to a BP for a to low price so that the revenue has an insufficient effect on the PPHM PPS to be able to buy a meaningful amount of shares of that BP because within a BP there are other things and one would not just be buying in on PS-targeting. GILD, JNJ, PFE and Novartis are a few examples.

If they sell for cash they know they had about 500+Mil$ invested in the PS-Targeting program in losses + the part we didn't see because AVID income compensated the last years. Every 45Mil$ we will go up 1$ Per share. So about 22$ per Bil$. Add to that the value of AVID that will be somewhere between 8-10$ and the Tax write offs we have and we would at a sell of 1Bil$ PS-IP+Pipelines IO, Chemo, Radio, CAR-T, Viral, etc) be at about 30+$. Given this program took 15+ years 1Bil$ would NOT be a very good price for a total sell of PS-targeting incl. bio-markers and exosomes.

Furthermore we must make sure that the AVID profits would not flow away to paying PS related licensing to the buyer if the patents would be used by the mentioned Avid platforms.

The strange thing is that we invested in PS-targeting and this BoD makes it a CDMO without asking us what we shareholders want. The REAL leverage of our investment is in PS-Targeting, not in Avid.

AIMO

Peregrine Pharmaceuticals the Microsoft of Biotechnology! All In My Opinion. I am not advising anything, nor accusing anyone.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News